Anzeige
Erschienen in:
21.01.2017 | Original Paper
Intravitreal anti-VEGF treatment for subretinal neovascularisation secondary to type 2 idiopathic juxtafoveolar telangiectasia
Erschienen in: International Ophthalmology | Ausgabe 1/2018
Einloggen, um Zugang zu erhaltenAbstract
Purpose
To assess the long-term outcome of patients with subretinal neovascular membrane (SRNVM) secondary to type 2 idiopathic juxtafoveolar telangiectasia (IJT) receiving intravitreal anti-VEGF (vascular endothelial growth factor) injections.
Methods
A total of 14 eyes of 12 patients treated with intravitreal anti-VEGF for SRNVM related to type 2 IJT were retrospectively assessed.
Results
Nine men and 3 women with a mean age of 66 years (SD 12, range 47–87 years) were diagnosed with IJT-related SRNVM. On average, 6.8 injections (SD 5.5, range 3–18) were given per eye. Ten eyes were treated with ranibizumab, 3 eyes with bevacizumab and 1 eye received both substances. The median follow-up after the last injection was 31 months (IQR: 18, 48). In 6 eyes, BCVA improved by 1–4 lines (mean Δ +2.0 lines), 1 eye remained stable and 7 eyes showed decline of vision by 1–5 lines (mean Δ −2.1 lines). The baseline central foveal thickness was significantly reduced from a mean of 323 (SD 87) to 266 µm (SD 71 µm) at the last follow-up visit (p = 0.001).
Conclusions
SRNVM development is a severe complication of type 2 IJT. Since the establishment of intravitreal anti-VEGF treatment laser coagulation and PDT have lost significance. Intravitreal anti-VEGF therapy seems to be safe and effective for the treatment of IJT-related SRNVM. Frequently multiple intravitreal injections are necessary for stabilisation.